sanofi kk
- Company typePrivate
- Founded-
- HeadquartersTokyo, Japan
- Headcount—
- GTM typeB2B
- OfferingHardware or Manufacturing
sanofi kk firmographics
Firmographics- Name
- sanofi kk
- Legal name
- サノフィ株式会社
- Website
- https://sanofi.co.jp
- Company type
- Private
- Operating status
- Operating
- Ownership category
- akta.pro rank
sanofi kk industry classification
Industry- Product category
- Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)
- akta.pro secondary industries
- Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD), Consent, Documentation & Certification (Records/Passports/Proof of Vaccination) (HLAJAHAM), Health Informatics & Digital Health Programs (EDAHAGAJ)
Keywords
Where sanofi kk is headquartered
LocationHeadquarters
- HQ city
- Tokyo
- HQ country
- Japan
- HQ region
- Asia
Offices1 record
Markets served
sanofi kk business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
Revenue model
- Prescription Pharmaceuticals: Sale of prescription drugs across multiple therapeutic areas including immunology, neurology, oncology, rare blood disorders, rare diseases, diabetes, and cardiovascular disease
- Vaccines: Development and sale of vaccines including yellow fever vaccine
- Generic and Biosimilar Products: Sale of generic versions of insulin products and bio-similar products
Go-to-market motion1 record
Distribution channels2 records
Marketing channels7 records
sanofi kk product offering
Product offeringCore offering
Sanofi K.K. is the Japanese operating subsidiary of global biopharmaceutical company Sanofi S.A., headquartered in Tokyo. The company develops, manufactures, and commercializes prescription medicines, vaccines, and biosimilars across therapeutic areas including immunology, neurology, oncology, rare blood disorders, rare diseases, diabetes, and cardiovascular disease. It also markets a digital health companion app and a medical device for insulin delivery.
Product overview
Sanofi KK is a research and development-driven, AI-powered global biopharmaceutical company operating in Japan. The company's product portfolio spans multiple therapeutic areas including immunology, oncology, neurology, rare blood disorders, rare diseases, diabetes, and cardiovascular diseases. Key products include insulin analogs (Apidra, Lantus) and biosimilar insulins delivered via SoloStar pen devices, specialty pharmaceuticals like Dupixent and Sarclisa, vaccines including Menquadfi and Yellow Fever Vaccine, and the SoloSmart connected smart insulin pen system. The company also operates patient support initiatives such as the MMoving Forward global multiple myeloma program and maintains environmental sustainability commitments through its Planet Mobilization strategy.
Differentiator
Problem solved
Functional benefit
Brands
- SoloSmart®: Digital health application for diabetes patients using smart insulin pens; compatible software application that helps patients track insulin dosing, blood glucose, and other diabetes management data
- DM-TOWN
- MMoving Forward
- La Maison Business Support Center (LMBC)
- Chasing Miracles
Products and services
- Lantus SoloStar
- Apidra SoloStar
- Dupixent (dupilumab)
- Sarclisa (isatuximab)
- Elplat (oxaliplatin)
Companies that use sanofi kk
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles1 record
sanofi kk technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
sanofi kk partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- MMoving Forward AlliancecoreGlobal initiative bringing together multiple myeloma experts, patient advocacy groups, and healthcare professionals to improve patient outcomes and quality of life. Alliance includes International Myeloma Foundation, Myeloma UK, Myeloma Patients Europe, and various academic and clinical experts worldwide.
- International Myeloma FoundationcoreRepresented by Yelak Biru (President), part of the MMoving Forward Alliance focusing on patient unmet needs and quality of life improvements
- Myeloma UKcoreRepresented by Sophie Castell (CEO), contributing to shared decision-making and patient engagement initiatives
- Myeloma Patients EuropecoreRepresented by Katie Joyner (Co-CEO) and Diane Loening-Martens (Vice President), supporting patient-centered care and quality of life improvements
- くすりの適正使用協議会 (RAD-AR)minorPartnership for patient education on proper medication usage and safety information
- European Oncology Nursing Society (EONS)minorNursing society contributing to patient care journey improvements in multiple myeloma through nursing role development
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
sanofi kk competitors and assessment
Company assessmentDirect peers
- MSD Japan (Merck): Japanese subsidiary of a global pharma; directly competes with Sanofi in vaccines, oncology, immunology, and diabetes via the same MR-to-pharmacy/hospital distribution.
- Chugai Pharmaceutical: Roche-affiliated Japanese pharma leader with biologics and specialty therapeutics in immunology and oncology; directly comparable as a multinational-pharma Japanese subsidiary competing in Sanofi's core franchises.
- Novartis Pharma Japan: Japanese operating arm of a global pharma; serves the same hospital, specialty, and rare-disease channels with overlapping cardiovascular, neurology, and immunology product lines.
- Takeda Pharmaceutical: Largest Japanese-headquartered global pharma; competes with Sanofi K.K. across immunology, rare diseases, oncology, neurology, and diabetes in the Japan market with overlapping HCP and patient segments.
- Bayer Yakuhin: Japanese pharma arm of a global life sciences group; competes in cardiovascular, oncology, women's health, and imaging products through overlapping hospital and pharmacy channels.
- Daiichi Sankyo: Top-tier Japanese pharma with oncology and specialty franchises; competes with Sanofi in oncology and rare disease products distributed through the same hospital and pharmacy channels.
- AstraZeneca Japan: Japanese subsidiary of a global biopharma; overlaps Sanofi in oncology, cardiovascular, respiratory, and rare disease categories sold to the same Japanese HCPs.
- Roche Japan: Japanese subsidiary of a global pharma; competes in oncology, immunology, and diagnostics-adjacent digital health offerings parallel to Sanofi's portfolio strategy.
- Astellas Pharma: Major Japanese pharma with oncology, immunology, and neurology franchises that overlap Sanofi's therapeutic areas in the same Japanese commercial channels.
- Pfizer Japan: Japanese subsidiary of a global biopharma; competes head-to-head with Sanofi K.K. across vaccines, oncology, immunology, and rare diseases served through the same MR-led channel model.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
sanofi kk social profiles
Digital presencesanofi kk financial estimates
Financial estimateRevenue estimate
Valuation estimate
sanofi kk leadership team
Management profileNumber of profiles
Profiles1 record
sanofi kk subsidiaries and ownership
Company hierarchySubsidiaries3 records
sanofi kk funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
sanofi kk M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about sanofi kk
What does sanofi kk do?
Sanofi K.K. is the Japanese operating subsidiary of global biopharmaceutical company Sanofi S.A., headquartered in Tokyo. The company develops, manufactures, and commercializes prescription medicines, vaccines, and biosimilars across therapeutic areas including immunology, neurology, oncology, rare blood disorders, rare diseases, diabetes, and cardiovascular disease. It also markets a digital health companion app and a medical device for insulin delivery.
Is sanofi kk a public or private company?
sanofi kk is a private company. It is classified as corporate owned and is currently operating.
When was sanofi kk founded?
sanofi kk was founded in -1.
Where is sanofi kk based?
sanofi kk is headquartered in Tokyo, Japan, in the Asia region.
How does sanofi kk make money?
Three revenue lines are on record. Prescription Pharmaceuticals are the primary driver. The others are vaccines and generic and Biosimilar Products.
Who are sanofi kk's main competitors?
Direct peers on record are MSD Japan (Merck), Chugai Pharmaceutical, Novartis Pharma Japan, Takeda Pharmaceutical, Bayer Yakuhin, Daiichi Sankyo, AstraZeneca Japan, Roche Japan, Astellas Pharma and Pfizer Japan.
Does sanofi kk have an API?
No public API is recorded for sanofi kk.
What industry is sanofi kk in?
sanofi kk's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors), with a secondary code of HLAIACAD, Endocrinology & Metabolic Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.